Company: IMNN
Filing Date: 2025-03-24
Form Type: 8-K
Source: 0001641172-25-000207
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-03-24
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

On
March 24, 2025, Imunon, Inc. (the “ Company”) issued a press release announcing finalization with the U. S. Food and Drug Administration
for the Company’s Phase 3 study design for IMNN-001 to develop treatment for women with newly diagnosed advanced ovarian cancer.
The Company also announced that it will host a conference call to discuss the Phase 3 OVATION 3 trial on Tuesday, March 25, 2025 at 2:00
p. m., Eastern Time, and a live webcast of the call will be available through the News & Investors - Scientific Presentations
section of the Company’s website. A replay will also be posted there shortly after the conference call ends.

A
copy of the press release issued by the Company, dated March 24, 2025, is attached hereto as Exhibit 99.1 to this Form 8-K.